HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new ...
The QX Continuum Droplet Digital™ PCR (ddPCR™) System* combines a simple workflow with sensitivity and precision, empowering researchers to explore a wide range of applications. From detecting subtle ...
News-Medical.Net on MSN
Biodesix announces expanded Bio-Rad Laboratories partnership agreement to develop Droplet Digital™ PCR high complexity assays
Biodesix, Inc., a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement ...
Scientists manufacture many biotherapeutic products in immortalized cell lines, most commonly HEK293. Residual HEK293 DNA in biotherapeutic candidates can harbor tumorigenic or retroviral sequences ...
Ultra-rapid digital droplet PCR can measure the levels of tumor cells in a tissue sample in about 15 minutes. (HealthDay News) — Intraoperative ultra-rapid droplet digital polymerase chain reaction ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced today that the company’s management will host an informational ...
We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Bio-Rad Laboratories, Inc. stands tenth on our list and is currently making waves for launching a new ...
Philadelphia, March 27, 2025 – Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), ...
Source: Bio-Rad Laboratories, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback